• Home
  • >
  • Suven Life Sciences Ltd Financials
https://storage.googleapis.com/assets.cdp.blinkx.in/Blinkx_Website/icons/suven-life-sciences-ltd.png Logo

Suven Life Sciences Ltd Financial Statement

Suven Life Sciences Ltd Income Statement
Quarterly
Annual

*All values are in Rs. Cr

(Rs. CR)Mar 2024Dec 2023Sep 2023
Revenue6.678.5215.66
Operating Expense9.2511.6511.13
Net Profit-3.12-4.772.76
Net Profit Margin-46.78-55.9917.62
Earning Per Share-0.14-0.220.13
EBIDTA-2.58-3.134.53
Effective Tax Rate38.61TBATBA

(Rs. Cr)

Revenue

Operating Expense

Net Profit

Net Profit Margin

Earning Per Share

EBIDTA

Effective Tax Rate

Suven Life Sciences Ltd Profit & Loss

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Total Revenue Annual13.5411.8413.48
Operating Expenses Annual139.42134.2393.54
Operating Profit Annual-111.44-117.07-72.31
Interest Annual0.290.530.82
Depreciation6.524.374.33
Net Profit Annual-118.27-122-72.15
Tax AnnualTBATBA-5.32

Particulars

Total Revenue Annual

Operating Expenses Annual

Operating Profit Annual

Interest Annual

Depreciation

Net Profit Annual

Tax Annual

Suven Life Sciences Ltd Cash Flow

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Cash Flow at the Beginning5.279.3514.68
Cash Flow from Operations-103.15-127.54-96.02
Cash Flow from Investing-260.65-22.2355.84
Cash Flow from Financing395.54145.6934.86
Cash Flow at the End37.025.279.35

Particulars

Cash Flow at the Beginning

Cash Flow from Operations

Cash Flow from Investing

Cash Flow from Financing

Cash Flow at the End

Suven Life Sciences Ltd Key Ratios

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
PBDIT Margin (%)-821.12-987.58-535.53
PBIT Margin (%)-869.42-1,024.66-567.8
PBT Margin (%)740.77504.8236.13
Net PROFIT Margin (%)-148.67-306.17-167.88
Return On Networth / Equity (%)TBATBATBA
Return On Networth /Employed(%)TBATBATBA
Return On Assets (%)-8.92-33.68-16.79
Total Debt / Equity(X)TBA0.010.01
Asset Turnover Ratio (%)0.060.110.1

Particulars

PBDIT Margin (%)

PBIT Margin (%)

PBT Margin (%)

Net PROFIT Margin (%)

Return On Networth / Equity (%)

Return On Networth / Employed(%)

Return On Assets (%)

Total Debt / Equity(X)

Asset Turnover Ratio (%)

Suven Life Sciences Ltd Balance Sheet

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Fixed Assets Annual37.2137.5620.96
Total Current Assets Annual251.5966.59102.68
Non Current Assets Annual137.3241.4425.74
Total Shareholders Funds Annual375.3296.15108.01
Total Assets Annual388.91108.03128.42

Particulars

Fixed Assets Annual

Total Current Assets Annual

Non Current Assets Annual

Total Shareholders Funds Annual

Total Assets Annual

Suven Life Sciences Ltd Earning Calls
Mar 2024
EPS beaten by 0.00 %

Open Demat Account

50years
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O

Dividend Pages

PE Ratio

Get Your FAQs Right

As of May 20, 2024, Suven Life Sciences Ltd has a market capitalization of 2,174.19 Cr. Value Research classifies it as a Mid-Cap company.

Yes, Suven Life Sciences Ltd is debt-free with a debt-to-equity ratio of 0.00.

In FY 2023, Suven Life Sciences Ltd recorded a total revenue of approximately 11.69 Cr marking a significant milestone in the company's financial performance.

Suven Life Sciences Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.2% and -0.0% annually, respectively..

Suven Life Sciences Ltd's current PE ratio is -20.69.

Suven Life Sciences Ltd's ROCE averaged -64.2% from the FY ending March 2022 to 2024, with a median of -39.1%. It peaked at -31.3% in March 2023, reflecting strong capital efficiency over the period..

Suven Life Sciences Ltd's latest EBIT is Rs. -105.92 Cr, surpassing the average EBIT of Rs. -115.12 Cr over the 5 years..